Indeed, in recent years, expanding treatment options in MDS have included some important novel therapies for anaemia in RS-MDS, like luspatercept, which has proven to be more effective than EPO in LR-MDS patients and those affected by SF3B1-mutant MDS [97]. This evidence concerns the gene EPO and myelodysplastic syndrome.